Popular terms

Kinetics topics
Medical Device
Polypeptide
Nucleic Acid
Nucleic Acids
Specificity
Surfactant
Enhancement
Scattering
Electrolyte
Conductive Elements
Amplification
Red Blood Cell
Red Blood Cells
Antibodies
Luciferase

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Kinetics patents



      

This page is updated frequently with new Kinetics-related patent applications.




Date/App# patent app List of recent Kinetics-related patents
06/23/16
20160174534 
 Genetically modified rat models for pharmacokinetics patent thumbnailGenetically modified rat models for pharmacokinetics
The present invention provides a desired rat or a rat cell which contains a predefined, specific and desired alteration rendering the rat or rat cell predisposed to drug transport sensitivity or resistance drug transport resistance or sensitivity. Specifically, the invention pertains to a genetically altered rat, or a rat cell in culture, that is defective in at least one of two alleles of a drug transporter gene such as the slc7a11 (nc_005101.2) gene, the abcb1 (nc_005103.2) gene, etc.

06/16/16
20160171183 
 Simulation of endogenous and exogenous glucose/insulin/glucagon interplay in type 1 diabetic patients patent thumbnailSimulation of endogenous and exogenous glucose/insulin/glucagon interplay in type 1 diabetic patients
A simulator for in-silico testing of type 1 diabetes patients uses a model that puts in relation plasma concentrations, i.e., glucose g and insulin /, with glucose fluxes, i.e. Endogenous glucose production (egp), glucose rate of appearance (ra), glucose utilization by the tissues (u), renal extraction (e), and insulin fluxes, i.e., rate of insulin appearance from the subcutaneous tissues (sc) and insulin degradation (d).
University Of Virginia Patent Foundation


06/16/16
20160169914 
 Kinetics biomarkers for neurodegeneration patent thumbnailKinetics biomarkers for neurodegeneration
The present invention relates to novel diagnostic, prognostic, predictive and pharmacodynamic properties with regard to amyotrophic lateral sclerosis (als) and/or parkinson's disease (pd) with and without dementia components. The methods described herein will prove very useful in the development of diagnostic as well as treatment strategies for patients with amyotrophic lateral sclerosis (als) and/or parkinson's disease (pd)..
Kinemed, Inc.


06/09/16
20160161379 
 In situ chemical transformation and ionization of inorganic perchlorates on surfaces patent thumbnailIn situ chemical transformation and ionization of inorganic perchlorates on surfaces
A method for providing in situ chemical transformation and ionization of a portion (e.g., inorganic oxidizer) of a sample via an analyte detection system is disclosed herein. The method includes introducing a gas into an ionization source of the analyte detection system via an inlet.
Smiths Detection Montreal Inc.


06/09/16
20160159915 
 Antibody constant region variant patent thumbnailAntibody constant region variant
By means of amino acid sequence alterations, the present inventors succeeded in providing constant regions that can confer antibodies with favorable properties, particularly as pharmaceuticals. The variants of the constant regions provided by the present invention will remarkably reduce heterogeneity when applied to antibody production.
Chugai Seiyaku Kabushiki Kaisha


06/09/16
20160157971 
 Controlling of sintering kinetics of oxide ceramics patent thumbnailControlling of sintering kinetics of oxide ceramics
The invention relates to multi-layer oxide ceramic bodies and in particular to presintered multi-layer oxide ceramic blanks and oxide ceramic green bodies suitable for dental applications. These bodies can be thermally densified by further sintering without distortion and are thus particularly suitable for the manufacture of dental restorations.
Ivoclar Vivadent Ag


06/02/16
20160154004 
 Device and  determining reaction kinetics patent thumbnailDevice and determining reaction kinetics
Or to derive a temperature-dependent activation energy if that is more appropriate for the chemical species of interest.. .

06/02/16
20160153973 
 Device and  rapid linker mediated label-based immunoassays patent thumbnailDevice and rapid linker mediated label-based immunoassays
A method and system is provided which uses cleavable linkers to detect an analyte in an immunoassay. The use of linkers in elisa and similar immunoassay protocols allows for a reduction in wash steps, incubation time, and potential for user error.

06/02/16
20160153000 
 Non-toxic hsv vectors for efficient gene delivery applications and complementing cells for their production patent thumbnailNon-toxic hsv vectors for efficient gene delivery applications and complementing cells for their production
The invention provides a herpes simplex virus (hsv) vector that does not express toxic hsv genes in non-complementing cells and which comprises a genome comprising one or more transgenes, wherein the vector is capable of expression of a transgene for at least 28 days in non-complementing cells. The disclosed vectors include vectors having deletions in the genes icp0, icp4, tcp22, tcp27 and tcp47, or alternative inactivating mutations, or vectors which express one or more of these genes with modified kinetics.
University Of Pittsburgh - Of The Commonwealth System Of Higher Education


06/02/16
20160152685 
 Small molecule-dependent inteins and uses thereof patent thumbnailSmall molecule-dependent inteins and uses thereof
Elucidating the function of proteins in mammalian cells is particularly challenging due to the inherent complexity of these systems. Methods to study protein function in living cells ideally perturb the activity of only the protein of interest but otherwise maintain the natural state of the host cell or organism.
President And Fellows Of Harvard College


05/19/16
20160139077 

Apparatus for analyzing ion kinetics in dielectrics


An apparatus for analyzing ion kinetics in a dielectric probe structure includes an ion reservoir abutting the dielectric probe structure and configured to supply mobile ions to the dielectric probe structure, a capacitor structure configured to generate an electric field in the dielectric probe structure along a vertical direction, and an electrode structure configured to generate an electrophoretic force on mobile ions in the dielectric probe structure along a lateral direction. A method for analyzing ion kinetics in the dielectric probe structure of the apparatus is also provided..
Infineon Technologies Ag


05/12/16
20160130673 

Nucleic acid detection by oligonucleotide probes cleaved by both exonuclease and endonuclease


Disclosed is a method in the fields of biochemistry and molecular biology. The method is related to improve cleavage kinetics of labeled oligonucleotide probes and, consequently, increases signal-to-noise ratio in detecting nucleic acids..
Samsung Techwin Co., Ltd.


04/28/16
20160114050 

Heparosan/therapeutic prodrug complexes and methods of making and using same


Compositions, methods, and systems are disclosed for the development and use of heparosan, a natural polymer related to heparin, as a new therapeutic modifying agent or complexation vehicle which can modulate drug cargo pharmacokinetics and behavior within a mammalian patient. In certain non-limiting embodiments, the use of heparosan is complexed with anti-cancer drugs and the like, thus forming a prodrug for the purposes of increasing efficacy and reducing side effects compared to the parental drug alone..
The Board Of Regents Of The University Of Oklahoma


04/21/16
20160108115 

Anti-c5 antibodies having improved pharmacokinetics


The disclosure provides antibodies that are useful for, among other things, inhibiting terminal complement (e.g., the assembly and/or activity of the c5b-9 tcc) and c5a anaphylatoxin-mediated inflammation and, thus, treating complement-associated disorders. The antibodies have a number of improved properties relative to eculizumab, including, e.g., increased serum half-life in a human..

04/21/16
20160108048 

Imidazole derivatives and methods of use thereof for improving the pharmacokinetics of a drug


The present invention relates to imidazole derivatives of formula (i), and pharmaceutically acceptable salts thereof, wherein a, b, y, r1 and r2 are as defined herein. The present invention also relates to compositions comprising at least one imidazole derivative, and methods of using the imidazole derivatives for inhibiting cyp450 3a.

04/21/16
20160106839 

Tamper resistant dosage form comprising inorganic salt


The invention relates to a pharmaceutical dosage form exhibiting a breaking strength of at least 500 n, said dosage form containing a pharmacologically active ingredient (a); an inorganic salt (b); and a polyalkylene oxide (c) having a weight average molecular weight of at least 200,000 g/mol, wherein the content of the polyalkylene oxide (c) is at least 20 wt.-%, based on the total weight of the dosage form; wherein the pharmacologically active ingredient (a) is present in a controlled-release matrix comprising the inorganic salt (b) and the polyalkylene oxide (c) and wherein, under in vitro conditions, the release profile of the pharmacologically active ingredient (a) from said matrix comprises at least a time interval during which the release follows zero order kinetics.. .

04/21/16
20160106683 

Timed, pulsatile release systems


A unit multiparticulate dosage form for delivering one or more basic, active pharmaceutical ingredients into the body in need of such medications to achieve target pk (pharmacokinetics) profiles is described. The dosage form comprises one or more multicoated drug particles (beads, pellets, mini-/micro-tablets) having a barrier coating and a lag-time coating.

04/14/16
20160101061 

Pharmaceutical carrier device suitable for delivery of pharmaceutical compounds to mucosal surfaces


The present invention relates to a pharmaceutical delivery device for application of a pharmaceutical to mucosal surfaces. The device comprises an adhesive layer and a non-adhesive backing layer, and the pharmaceutical may be provided in either or both layers.

04/07/16
20160096820 

Inhibitors of inv(16) leukemia


This invention describes the development of targeted small molecule inhibitors of the inv(16) fusion, the causative agent in ˜12% of acute myeloid leukemia (aml). The inv(16) fusion results in expression of the cbfβ-smmhc fusion protein in the blood cells of afflicted patients.
University Of Virginia Patent Foundation


04/07/16
20160095865 

Application of enrofloxacin salt in preparation of oral preparation for pigs


The invention discloses application of an enrofloxacin salt in preparation of an oral preparation for pigs. The enrofloxacin salt is at least one of salts formed by enrofloxacin and metal ions, and the metal ions are zinc, copper, calcium, magnesium, iron, cobalt, manganese, chromium, silver or nickel.
Guangzhou Insighter Biotechnology Co., Ltd.


03/24/16
20160084817 

Method to enhance exploration, development and production of hydrocarbons using multiply substituted isotopologue geochemistry, basin modeling and molecular kinetics


A method and system are described that may be used for exploration, production and development of hydrocarbons. The method and system may include analyzing a sample for a geochemical signature, wherein the geochemical signature includes a multiply substituted isotopologue signature and/or a position specific isotope signature.

03/24/16
20160084080 

Method to enhance exploration, development and production of hydrocarbons using multiply substituted isotopologue geochemistry, basin modeling and molecular kinetics


A method and system are described that may be used for exploration, production and development of hydrocarbons. The method and system may include analyzing a sample for a geochemical signature, wherein the geochemical signature includes a multiply substituted isotopologue signature and/or a position specific isotope signature.

03/24/16
20160083753 

Metabolic evolution of escherichia coli strains that produce organic acids


This invention relates to the metabolic evolution of a microbial organism previously optimized for producing an organic acid in commercially significant quantities under fermentative conditions using a hexose sugar as sole source of carbon in a minimal mineral medium. As a result of this metabolic evolution, the microbial organism acquires the ability to use pentose sugars derived from cellulosic materials for its growth while retaining the original growth kinetics, the rate of organic acid production and the ability to use hexose sugars as a source of carbon.
Myriant Corporation


03/24/16
20160083450 

Human protein scaffold with controlled serum pharmacokinetics


This invention provides constructs comprising a protein scaffold, wherein the scaffold comprises domain iii, domain iiia, or domain iiib of human serum albumin or a polypeptide having substantial sequence identity to the domain iii, the domain iiia, or the domain iiib; and a targeting moiety in covalent linkage to the protein scaffold; and a therapeutic moiety and/or an imaging moiety in covalent linkage to the protein scaffold. The scaffold can be modified to tune the serum pharmacokinetics of the construct.
The Regents Of The University Of California


03/24/16
20160082136 

Metal complexes and fluorination thereof


A method of labelling biological molecules with 18f, via attachment of fluorine to a metal complex, where the metal complex is conjugated to the biological molecule. The invention highlights the incorporation of hydrogen bonding (h-bonding) into the metal complex scaffold, and how this can be utilised to improve the kinetics of fluoride incorporation.
University Of Southampton


03/17/16
20160075821 

Method to manufacture pla using a new polymerization catalyst


The invention relates to a method for manufacturing polylactide, comprising the steps of mixing lactide and a metal-coordination compound as polymerization catalyst to obtain a reaction mixture, polymerizing the lactide in liquid phase at a temperature of at least 150° c. To form polylactide in liquid phase and allowing the polylactide to solidify, characterized in that the polymerization catalyst comprises a metal-ligand coordination compound whereby the parent ligand answers the formula (i), whereby r represents an h atom, an aliphatic group, a halide atom or a nitro group and the metal is at least one of zr and hf.
Purac Biochem Bv


03/17/16
20160075820 

Synthesis and molecular weight control of aliphatic polyester diols


The synthesis of certain polyester diols (peds) is disclosed. This application also discloses the purification and polymerization kinetics of lipid based peds.
Trent University


03/17/16
20160074540 

Metal complexes and their fluorination


A method of labelling biological molecules with 18f, via attachment of fluorine to a metal complex, where the metal complex is conjugated to the biological molecule. The invention highlights the incorporation of hydrogen bonding (h-bonding) into the metal complex scaffold, and how this can be utilised to improve the kinetics of fluoride incorporation.
University Of Southampton


03/17/16
20160074399 

Salts of an epidermal growth factor receptor kinase inhibitor


The present invention provides a salt form and compositions thereof, which are useful as an inhibitor of egfr kinases and which exhibits desirable characteristics for the same. Examples include hydrobromide and bis-besylate salts of n-(3-(2-(4-(4-acerylpiperazin-1-yl)-2-methoxyphenylamino)-5-(trifluoromethyl)pyrimidin-4-ylamino)phenyl)acrylamide).
Clovis Oncology, Inc.


03/17/16
20160074333 

Pharmaceutical compositions of tamsulosin or salts thereof


The present invention relates to pharmaceutical compositions of tamsulosin or salts thereof. In particular, the invention relates to pharmaceutical compositions comprising a core of tamsulosin or salts, hydrates thereof and at least one specialized coating over the core.
Wockhardt Limited


03/17/16
20160073964 

Retrospective retrofitting method to generate a continuous glucose concentration profile by exploiting continuous glucose monitoring sensor data and blood glucose measurements


Continuous glucose monitoring (cgm) devices provide glucose concentration measurements in the subcutaneous tissue with limited accuracy and precision. Therefore, cgm readings cannot be incorporated in a straightforward manner in outcome metrics of clinical trials e.g.
UniversitÀ Degli Studi Di Padova Area Trasfermiento Di Tecnologia


03/10/16
20160069913 

Microfluidic chip-based, universal coagulation assay


A microfluidic, chip-based assay device has been developed for measuring physical properties of an analyte (particularly, whole blood or whole blood derivatives). The technologies can be applied to measure clotting times of whole blood or blood derivatives, determine the effects of anticoagulant drugs on the kinetics of clotting/coagulation, as well as evaluate the effect of anticoagulant reversal agents.
Perosphere Inc.


03/10/16
20160069858 

Rapid allergy testing method


The present invention provides a method for testing an allergy capable of rapidly and highly accurately testing an allergic reaction. The method can determine whether or not a patient has an allergy or whether or not an agent that may be allergenic to a patient has an allergenicity (an allergic reactivity) in the patient.

03/10/16
20160068588 

Antibodies with modified isoelectric points and immunofiltering


The invention relates generally to compositions and methods for altering the isoelectric point of an antibody, and in some cases, resulting in improved plasma pharmacokinetics, e.g. Increased serum half-life in vivo..
Xencor, Inc.


03/10/16
20160067217 

Metabolic syndrome treatment


Formulations and methods of providing an orally-active anti-metabolic disease fixed dose combinations (fdc) for use as personalized medicine to treat different components of the metabolic syndrome or insulin resistance syndrome such as type ii diabetes, hypertension, hyperlipidemia and obesity are disclosed. Pharmaceutical compositions of anti-inflammatory centric drug formulations and methods comprising of nsaids in general and selective cox-2 inhibitors in particular and one or more anti-t2dm or anti-hypertensive or anti-hyperlipidemic or anti-obesity drugs formulated to exhibit pre-determined modified release kinetics to achieve therapeutic as well as kinetic synergies are disclosed..
Arkay Therapeutics, Llc


03/03/16
20160060337 

Methods for treating psoriasis using an anti-il-23 antibody


The invention relates to products and methods for treating psoriasis. The products relate to antibodies that inhibit native human il-23 while sparing il-12.
Amgen Inc.


02/25/16
20160052993 

Albumin variants binding to fcrn


The invention relates to methods of identifying albumin variants having improved pharmacokinetics, albumin variants having improved pharmacokinetics, and therapeutic uses of albumin variants having improved pharmacokinetics.. .
Eleven Biotherapeutics, Inc.


02/25/16
20160051807 

Method and device for controlling drug pharmacokinetics


Methods and devices for administration of substances into at least two compartments of skin for systemic absorption and improved pharmacokinetics, based on biphasic or bimodel kinetic profiling.. .
Becton, Dickinson And Company


02/25/16
20160051640 

Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases


The invention relates to the discovery of novel soluble neutral active hyaluronidase glycoproteins (shasegps), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active shasegp domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain.
Halozyme, Inc.


02/18/16
20160049667 

Metal-air cell with performance enhancing additive


Systems and methods drawn to an electrochemical cell comprising a low temperature ionic liquid comprising positive ions and negative ions and a performance enhancing additive added to the low temperature ionic liquid. The additive dissolves in the ionic liquid to form cations, which are coordinated with one or more negative ions forming ion complexes.
Arizona Board Of Regents Acting For And On Behalf Of Arizona State University


02/18/16
20160047024 

Methods for processing titanium alloys


Methods of refining the grain size of a titanium alloy workpiece include beta annealing the workpiece, cooling the beta annealed workpiece to a temperature below the beta transus temperature of the titanium alloy, and high strain rate multi-axis forging the workpiece. High strain rate multi-axis forging is employed until a total strain of at least 1 is achieved in the titanium alloy workpiece, or until a total strain of at least 1 and up to 3.5 is achieved in the titanium alloy workpiece.
Ati Properties, Inc.


02/11/16
20160038431 

Timed, pulsatile release systems


A unit multiparticulate dosage form for delivering one or more basic, active pharmaceutical ingredients into the body in need of such medications to achieve target pk (pharmocokinetics) profiles is described. The dosage form comprises one or more multicoated drug particles (beads, pellets, mini-/micro-tablets) having a barrier coating and a lag-time coating.
Adare Pharmaceuticals, Inc.


02/04/16
20160033523 

Pharmacokinetic animal model


The present invention relates to a method of assessing pharmacokinetic properties of a variant of human serum albumin using a non-primate animal species where the native albumin of the animal provides minimal competition for hsa binding to the fcrn receptor in said animal. In the non-primate animal species, the binding affinity of wild type hsa to the native fcrn of said animal is the same as or higher than the binding affinity of the native albumin of said animal to the native fcrn.
University Of Oslo


02/04/16
20160031983 

Methods for treating crohn's disease using an anti-il23 antibody


The invention relates to products and methods for treating crohn's disease. The products relate to antibodies that inhibit native human il-23 while sparing il-12.
Amgen Inc.


02/04/16
20160030592 

Polyoxazoline antibody drug conjugates


In the present disclosure, polymer conjugates, including polymer-antibody-drug conjugates (polymer adcs) are described, as well as the use of such conjugates to treat human disease. The polymer conjugates can contain a large number of polymer-bound agents, thus effectively increasing the drug antibody ration (dar) of the antibody significantly beyond the currently available technology.
Serina Therapeutics, Inc.


01/28/16
20160024573 

Photocleavable deoxynucleotides with high-resolution control of deprotection kinetics


Provided herein are new classes of photocleavable deoxynucleotides that allow for more precise control over deprotection kinetics compared to previously described compounds. The compounds further feature more favorable solubility properties.
Ibis Biosciences, Inc.


01/28/16
20160022817 

Photoswitchable hdac inhibitors


This invention relates to photoswitchable inhibitors of histone deacetylases and methods of using the same. Provided herein are inhibitors of hdac having photoswitchable modulators of protein function with short thermal relaxation kinetics.
The General Hospital Corporation


01/28/16
20160022169 

Determination of physiological parameters of tissue from dynamic contrast-enhanced mr data


A method of determining microvascular architecture is disclosed. Dynamic contrast-enhanced magnetic resonance data acquired from a contrast agent administered to at least a part of a subject to be examined.
Koninklijke Philips N.v.


01/21/16
20160016821 

Novel cross-linked (bisphenol-s, formaldehyde, 1,6-hexadiamine) terpolymer for the adsorption of pb2+ ions from aqueous solutions


A cross-linked terpolymer (bsdf) obtained by polycondensation of bisphenol-s, formaldehyde and 1,6-diaminohexane. The terpolymer is highly efficient in eliminating lead ions from aqueous solutions.
King Fahd University Of Petroleum And Minerals


01/21/16
20160015698 

Pharmaceutical compositions of donepezil having specific in vitro dissolution profile or pharmacokinetics parameters


A timed release pharmaceutical composition comprising donepezil is provided wherein the single dose auc(14-22) of the said composition administered in the morning is about % to about 30% less than the single dose auc(2-10) of an immediate release composition of donepezil administered in the night, wherein both the compositions have equivalent dose of donepezil.. .
Lupin Limited


01/14/16
20160011169 

Nanopore sequencing methods


Methods are provided for sequencing of nucleic acid templates using nanopores. The rate of transport of the template nucleic acids through the nanopore is controlled using a polymerase enzyme having two slow kinetic steps.
Pacific Biosciences Of California, Inc.


01/14/16
20160010148 

Identifying modified bases using hemi-natural nucleic acids


Methods, compositions, and systems are provided for characterization of modified nucleic acids. Methods are provided for sequencing hemi-natural nucleic acids such as hemi-genomic dna, having two complementary strands, one a natural sequence and the other a synthetic sequence.
Pacific Bioscience Of California, Inc.


01/14/16
20160009818 

Anti-tfpi antibody variants with differential binding across ph range for improved pharmacokinetics


Antibodies are disclosed that bind to and inhibit the anti-coagulant function of tfpi and have a lower affinity for tfpi at ph 6.0 than at ph 7.4. The lower affinity at ph 6 improves circulating half-life (t½) due to reduced target mediated clearance, a process by which an antibody/antigen complex is endocytosed and trafficked to the lysosome where both components are degraded.
Bayer Healthcare Llc


01/14/16
20160008341 

Crystalline n-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mono mesylate monohydrate having a specific particle size distribution range and a specific surface area range for use in pharmaceutical formulations


The present invention relates to the crystalline mono mesylate monohydrate salt of n-[5-(amino sulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamide in a definite particle size range, particle size distribution and a specific surface area range, which has demonstrated increased long term stability and release kinetics from pharmaceutical compositions, as well as to pharmaceutical compositions containing said crystalline n-[5-(amino sulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mono mesylate monohydrate having the afore-mentioned particle size range, particle size distribution and specific surface area range. Moreover, the present invention relates to the pharmacokinetic and pharmacodynamic in vivo profiles of the resultant free base of n-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]-acetamide after administration of the afore-mentioned crystalline n-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]-acetamide mono mesylate monohydrate salt to a subject in need thereof..
Aicuris Gmbh & Co. Kg


01/14/16
20160008335 

Pharmaceutical compositions of donepezil having specific in vitro dissolution profile or pharmacokinetics parameters


A timed release pharmaceutical composition comprising donepezil is provided, wherein the composition exhibits the in vitro dissolution profile when tested in a paddle dissolution apparatus at 50 rpm in 900 ml 6.8 buffer at 37° c., less than about 20% w/w of donepezil is released in 3 to 6 hrs, and more than 90% w/w of donepezil is released after 12 hrs.. .
Lupin Limited


01/07/16
20160000923 

Drug delivery system to increase bioavailability


Disclosed herein are novel methods of treating diseases, novel dosage forms, and novel methods of modulating the pharmacokinetics of active ingredients.. .
Patheon Inc.


01/07/16
20160000806 

Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same


A drug delivery system for oral administration of hydrophobic drugs with enhanced and extended absorption and improved pharmacokinetics is provided. In one embodiment, formulations comprising testosterone and testosterone esters, e.g., testosterone palmitate, are disclosed.
Clarus Therapeutics, Inc.


01/07/16
20160000704 

Formulations of human tissue kallikrein-1 for parenteral delivery and related methods


Provided are high concentration compositions of tissue kallikrein-1 (klk1) and methods of parenterally administering such compositions to a subject in need thereof, where absorption into the circulation via, for example, intravenous or subcutaneous administration improves systemic pharmacokinetics, bioavailability, safety, and/or convenience relative to intravenous or other forms of administration. Also provided are recombinant human klk1 (rhklk1) polypeptides that can be readily concentrated to high protein concentrations, and substantially pure compositions thereof..
Diamedica Inc.


12/31/15
20150377894 

Method and system for measuring the pharmacokinetics of liposomal curcumin and its metabolite tetrahydrocurcumin


The present invention includes a stabilized curcumin composition. The composition includes a curcumin composition and a phosphate composition, wherein the phosphate composition is non-buffering and is provided in an amount sufficient to stabilize and/or prevent the degradation of curcumin and/or a curcuminoid in a biological sample..
Signpath Pharma Inc.


12/31/15
20150376803 

Gas diffusion electrodes and methods for fabricating and testing same


Highly effective, standalone gas-diffusion electrodes (gdes) and the methods for their manufacture and test are disclosed, nanocataiysis are directly bonded on a gas diffusion layer, so that the integrity of the catalyst layer holds without polymer electrolyte membrane, facilitating minimization of electronic, prottmtc, and diffusion resistances in the catalyst layer. The devised embodiments provide examples showing a facile hanging-strip method for testing the standalone gdes in a solution electrochemical cell, which removes the ma-cm−2-scale mass transport limited currents on rotating disk electrodes to allow studies of reaction kinetics on single electrode over sufficiently wide current ranges (up to a cm−2) without mass transport limitation.
Brookhaven Science Associates, Llc


12/31/15
20150376509 

Enhanced catalytic reactions in a coking process to improve process operation and economics


Heavy gas oil components, coking process recycle, and heavier hydrocarbons in the delayed coking process are cracked in the coking vessel by injecting a catalytic additive into the vapors above the gas/liquid-solid interface in the coke drum during the coking cycle. The additive may comprise cracking catalyst(s) and quenching agent(s), alone or in combination with seeding agent(s), excess reactant(s), carrier fluid(s), or any combination thereof to modify reaction kinetics to preferentially crack these components.

12/31/15
20150374722 

Once-a-week administration of 25-hydroxy vitamin d3 to sustain elevated steady-state pharmacokinetic blood concentration


An oral dosage form comprising a single dose of 25-hydroxy-vitamin d3 sufficient to elevate the serum level in a human to a concentration in the range of 30 ng/ml to 200 ng/ml for at least 7 days and a pharmaceutically suitable oral carrier system, wherein subsequent single doses at least every 7 days are sufficient to sustain the serum level in a human to a concentration in the range of 30 ng/ml to 200 ng/ml at steady-state pharmacokinetics is disclosed. A method of elevating and sustaining the blood level concentration of 25-hydroxy-vitamin d3 in a human in need thereof comprising orally administering or parenterally administering by injection or infusion, at least once every 7 days, a single dose of 25-hydroxy-vitamin d3 sufficient to elevate the serum level in a human to a concentration in the range of 30 ng/ml to 200 ng/ml for at least 7 days, wherein the single doses orally administered at least every 7 days are sufficient to sustain the serum level in a human to a concentration in the range of 30 ng/ml to 200 ng/ml at steady-state pharmacokinetics is disclosed.
Wisconsin Alumni Research Foundation


12/24/15
20150370962 

Pharmaceutical platform technology for the development of natural products


The present invention provides a set of in vitro and in silico methodologies for predicting in vivo pharmacokinetics and pharmacodynamics of multiple components; the methodologies comprise mathematical models for solving multiple unknowns which are linearly independent and/or interacting with each other. The present invention can be applied to develop phytomedicines which contain multiple active ingredients without prior identification, isolation and purification of these components..
Sinoveda Canada Inc.


12/24/15
20150368393 

Process for the extraction of polyhydroxyalkanoates from biomass


An industrial scale batch or semi-continuous batch pha extraction process wherein the process operating conditions and control may be quantitatively tuned to batch-to-batch variations based on a practical bench scale assessment but more preferably by means of a calibrated chemometric assessment of the biomass quality. Tuning involves the selection of biomass loading conditions that are commensurate with process solvent and pha type.
Veolia Water Solutions & Technologies Support


12/24/15
20150366849 

Crystalline n-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mono mesylate monohydrate having a specific particle size distribution range and a specific surface area range for use in pharmaceutical formulations


The present invention relates to the crystalline mono mesylate monohydrate salt of n-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamide in a definite particle size range, particle size distribution and a specific surface area range, which has demonstrated increased long term stability and release kinetics from pharmaceutical compositions, as well as to pharmaceutical compositions containing said crystalline n-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mono mesylate monohydrate having the afore-mentioned particle size range, particle size distribution and specific surface area range. Moreover, the present invention relates to the pharmacokinetic and pharmacodynamic in vivo profiles of the resultant free base of n-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]-acetamide after administration of the afore-mentioned crystalline n-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]-acetamide mono mesylate monohydrate salt to a subject in need thereof..
Aicuris Gmbh & Co. Kg


12/17/15
20150361091 

Oxazolidone compound, preparing method and application thereof


The present invention relates to the field of a pharmaceutical compound, and more specifically, relates to a new oxazolidone compound, an enantiomer, a diastereoisomer and a raceme thereof, and a mixture thereof, and a pharmaceutically acceptable salt thereof, a preparation method thereof, an application thereof as a bioactive substance in a drug. The compound in the present invention has strong anticoagulant activity, does not affect the activity of thrombin, and can reduce the risk of hemorrhage.
Zhe Jiang Jutai Pharmaceutical Co., Ltd


12/10/15
20150353911 

Chimeric clotting factors


The invention provides chimeric clotting factors comprising an activatable clotting factor and an enhancer moiety. The activatable clotting factor allows the chimeric clotting factor to be activated at the site of coagulation.
Biogen Idec Ma Inc.


12/10/15
20150353693 

Rapid fabrication of hierarchically structured supramolecular nanocomposite thin films in one minute


Functional nanocomposites containing nanoparticles of different chemical compositions may exhibit new properties to meet demands for advanced technology. It is imperative to simultaneously achieve hierarchical structural control and to develop rapid, scalable fabrication to minimize degradation of nanoparticle properties and for compatibility with nanomanufacturing.
The Regents Of The University Of California


12/10/15
20150352128 

Controlled release and taste masking oral pharmaceutical composition


Controlled release and taste masking compositions containing one or more active principles inglobated in a three-component matrix structure, i.e. A structure formed by successive amphiphilic, lipophilic or inert matrices and finally inglobated or dispersed in hydrophilic matrices.
Cosmo Technologies Limited


12/03/15
20150346104 

Sensing device, and sensing system and sensing method using the same


A sensing device applied to an analyte molecule of a liquid sample and a buffer flow has at least one first inlet, at least one second inlet, a micro-flow channel, and at least one immobilization element. The first inlet is for inputting the liquid sample.
Centre National De La Recherche Scientifique


12/03/15
20150343074 

Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same


A drug delivery system for oral administration of hydrophobic drugs with enhanced and extended absorption and improved pharmacokinetics is provided. In one embodiment, formulations comprising testosterone and testosterone esters, e.g., testosterone palmitate, are disclosed.
Clarus Therapeutics, Inc.


12/03/15
20150343073 

Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same


A drug delivery system for oral administration of hydrophobic drugs with enhanced and extended absorption and improved pharmacokinetics is provided. In one embodiment, formulations comprising testosterone and testosterone esters, e.g., testosterone palmitate, are disclosed.
Clarus Therapeutics, Inc.


12/03/15
20150343072 

Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same


A drug delivery system for oral administration of hydrophobic drugs with enhanced and extended absorption and improved pharmacokinetics is provided. In one embodiment, formulations comprising testosterone and testosterone esters, e.g., testosterone palmitate, are disclosed.
Clarus Therapeutics, Inc.


11/26/15
20150335954 

Method, apparatus, and computer program product for performance analytics determining play models and outputting events based on real-time data for proximity and movement of objects


Systems, methods, apparatuses, and computer readable media are disclosed for providing analytics using real time data on movement and proximity of tagged objects for determining play models and outputting events. In one embodiment, a method is provided for determining play data that at least includes correlating at least one tag to a participant; receiving blink data transmitted by the at least one tag; and determining tag location data based on the blink data.
Zih Corp.


11/26/15
20150335953 

Method, apparatus, and computer program product for performance analytics determining play models and outputting events based on real-time data for proximity and movement of objects


Systems, methods, apparatuses, and computer readable media are disclosed for providing analytics using real time data on movement and proximity of tagged objects for determining play models and outputting events. In one embodiment, a method is provided for determining play data that at least includes correlating at least one tag to a participant; receiving blink data transmitted by the at least one tag; and determining tag location data based on the blink data.
Zih Corp.


11/26/15
20150335952 

Method, apparatus, and computer program product for performance analytics determining play models and outputting events based on real-time data for proximity and movement of objects


Systems, methods, apparatuses, and computer readable media are disclosed for providing analytics using real time data on movement and proximity of tagged objects for determining play models and outputting events. In one embodiment, a method is provided for determining play data that at least includes correlating at least one tag to a participant; receiving blink data transmitted by the at least one tag; and determining tag location data based on the blink data.
Zih Corp.


11/19/15
20150332004 

Method and system to identify frailty using body movement


Systems and methods are disclosed which provide a way to diagnose frailty using an upper extremity (and/or other body portions) frailty assessment. Within this method, several parameters can be calculated based on the kinematics (e.g., pure motion without including forces) and kinetics (e.g., analysis of forces and moments) of, for example, joint flexion/extension.
The Arizona Board Of Regents On Behalf Of The University Of Arizona


11/19/15
20150328369 

Method of treating peripheral artery diseases in lower limbs


A method of treating peripheral artery diseases in lower limbs by providing a medical device having an expandable member having a drug coating layer which has a crystalline morphological form including a plurality of crystal particles of a water-insoluble drug regularly arranged and uniformly sized on the surface of the medical device, inserting the medical device in peripheral blood vessels, expanding the expandable member, pressing the drug coating layer to a blood vessel wall such that at least part of the plurality of crystals are transferred to the blood vessel wall, and deflating the expandable member such that a pharmacokinetics profile is presented in which a drug concentration in the blood vessels is kept for the inhibition of smooth muscle cell proliferation in a high drug-concentration period of time, and for the non-inhibition of endothelial cell growth in a later low drug-concentration period of time.. .
Terumo Kabushiki Kaisha


11/05/15
20150316533 

Methods and systems for point-of-care coagulation assays by optical detection


This invention relates to an optical system and method for performing turbidity assay, e.g. Coagulation of blood or plasma, comprising a standard optical reference, a sample handling structure, a light source and an optical detection unit.

11/05/15
20150315278 

Anti-glypican-3 antibody having improved kinetics in plasma


A method of modulating the plasma half-life of anti-glypican 3 antibody, a pharmaceutical composition comprising as an active ingredient the anti-glypican 3 antibody that has a plasma half-life that has been modulated, a method of preparing the anti-glypican 3 antibody and a pharmaceutical composition comprising the anti-glypican 3 antibody as an active ingredient are provided. Disclosed is a method of modulating the plasma half-life of anti-glypican 3 antibody by modifying an amino acid residue that is exposed on the surface of the anti-glypican 3 antibody; and anti-glypican 3 antibody that has a plasma half-life that has been modulated by amino acid residue modification, a pharmaceutical composition comprising as an active ingredient the anti-glypican 3 antibody, and a method of preparing the anti-glypican 3 antibody and producing a pharmaceutical composition comprising the anti-glypican 3 antibody as an active ingredient..
Chugai Seiyaku Kabushiki Kaisha


11/05/15
20150314010 

Potentiation of anticancer agents


The present invention relates to carriers, conjugate and pharmaceutical compositions and their use to increase the potency of drugs and to modify the pharmacokinetics of compounds. More particularly, the present invention relates to conjugates comprising the carrier described herein and their use in the treatment and diagnostic of cancer..
Angiochem Inc.


10/22/15
20150302169 

Method and system to extend the conditions of application of an inversion of the hodgkin-huxley gating model


A method to quantify kinetics of voltage gated membrane channels by inversion of a hodgkin huxley formalism includes the steps of: providing an electrophysiology apparatus configured to provide a constant voltage difference across a cell membrane of a cell and to measure a current through the cell membrane and a computer configured to run at least one or more protocols; bounding r based on data generated by a t-step protocol or a g-step protocol; estimating a steady state based on data generated by a c-step protocol or a h step protocol; extracting a time constant based on the data generated by the t-step protocol or the g-step protocol as bounded by r; and assessing a range of time constants that can reproduce the data generated by the c-step protocol or the h step protocol and by the t-step protocol or the g-step protocol within and experimental error. C-step and a g-step voltage clamp stimulation protocols to generate a set of experimental data to quantify a channel availability of a cell are also described..

10/22/15
20150299313 

Antigen-binding molecule for promoting clearance from plasma of antigen comprising suger chain receptor-binding domain


Disclosed are an antigen-binding molecule containing a sugar chain receptor-binding domain and having a weak antigen-binding activity in the ph of early-stage endosome compared to the antigen-binding activity in the ph of plasma; a pharmaceutical composition containing the antigen-binding molecule; and a method for producing these. Use of the antigen-binding molecule of the invention enables to promote uptake of an antigen into a cell and increase the number of antigens that a single antibody molecule can bind.
Chugai Seiyaku Kabushiki Kaisha


10/22/15
20150299305 

Anti-c5 antibodies having improved pharmacokinetics


The disclosure provides antibodies that are useful for among other things, inhibiting terminal complement (e.g., the assembly and/or activity of the c5b-9 tcc) and c5a anaphylatoxin-mediated inflammation and, thus, treating complement-associated disorders. The antibodies have a number of improved properties relative to eculizumab, including, e.g., increased serum half-life in a human..
Alexion Pharmaceuticals, Inc.


10/15/15
20150293110 

Compositions and methods for in vitro diagnostic tests including zwitterionic solubilization reagent


The disclosure is directed to compositions, kits, and methods for performing colorimetric analysis. A composition for a colorimetric assay can be prepared that includes an aromatic amine chromogenic substrate and a zwitterionic solubilization reagent that is n,n,n-trimethylglycine (betaine).

10/15/15
20150293077 

Methods for determining the effect of an agent on tissue stem cells


Herein, we describe a direct in vitro method that identifies agents that are toxic against natural human tissue stem cells. We provide a novel schedule for culturing any cell population containing homologous tissue stem cells that allows the number and cell kinetics of tissue stem cells, transient cells, and terminally differentiated cells within the population to be monitored.

10/15/15
20150291596 

Antiviral azasugar-containing nucleosides


Disclosed are compounds comprising an azasugar attached to a heterocyclic base, including pharmaceutically acceptable salts thereof, suitable for use in inhibiting viral rna polymerase activity or viral replication, and treating viral infections. The compounds are characterized, in part, by favorable pharmacokinetics for the active pharmaceutical ingredient, particularly in conjunction with enteral administration, including, in particular, oral administration.

10/15/15
20150290328 

Formulations of active agents for sustained release


The present invention provides pharmaceutical formulations for sustained release when administered at cold temperatures, and methods for delivering a treatment regimen with a combination of sustained release and long half-life formulations. The invention provides improved pharmacokinetics for peptide and small molecule drugs..

10/08/15
20150284518 

Enhancing the physical properties of semi-crystalline polymers via solid state shear pulverization


Solid-state shear pulverization of semi-crystalline polymers and copolymers thereof and related methods for enhanced crystallization kinetics and physical/mechanical properties.. .

10/08/15
20150284465 

Method of modifying isoelectric point of antibody via amino acid substitution in cdr


The present inventors provide methods for modifying the isoelectric point of an antibody while retaining its antigen-binding activity, comprising modifying the charge of at least one exposable amino acid residue on the surface of the complementarity determining region (cdr). The present invention also provides methods for purifying multispecific antibodies, comprising modifying isoelectric point, and methods for improving the plasma pharmacokinetics of antibodies, comprising modifying isoelectric point.

10/08/15
20150284352 

Methods for inhibiting drug degradation


Methods of inhibiting cytochrome p450 enzymes are provided that can be used for improving the treatment of diseases by preventing degradation of drugs or other molecules by cytochrome p450. Pharmaceutical compositions are provided that can act as boosters to improve the pharmacokinetics, enhance the bioavailability, and enhance the therapeutic effect of drugs that undergo in vivo degradation by cytochrome p450 enzymes..

10/08/15
20150283294 

Mesoporous calcium silicate compositions and methods for synthesis of mesoporous calcium silicate for controlled release of bioactive agents


Mesoporous calcium silicate compositions for controlled release of bioactive agents and methods for producing such compositions are disclosed herein. In one embodiment, mesoporous calcium silicate is synthesized by acid modification of wollastonite particles using hydrochloric acid.



Kinetics topics: Medical Device, Polypeptide, Nucleic Acid, Nucleic Acids, Specificity, Surfactant, Enhancement, Scattering, Electrolyte, Conductive Elements, Amplification, Red Blood Cell, Red Blood Cells, Antibodies, Luciferase

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Kinetics for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Kinetics with additional patents listed. Browse our RSS directory or Search for other possible listings.


3.4482

4563

73 - 0 - 102